448 related articles for article (PubMed ID: 26337241)
1. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
3. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
5. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
6. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
7. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
8. Emerging agents for the therapy of advanced prostate cancer.
Hathaway AR; Baker MK; Sonpavde G
Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474
[TBL] [Abstract][Full Text] [Related]
9. Metastatic castration-resistant prostate cancer: integrating new learnings to optimise treatment outcomes.
Heidenreich A; Porres D; Piper C; Thissen AK; Pfister D
Minerva Urol Nefrol; 2013 Sep; 65(3):171-87. PubMed ID: 23872628
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
Galletti G; Leach BI; Lam L; Tagawa ST
Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
[TBL] [Abstract][Full Text] [Related]
11. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
12. Current therapeutic options in metastatic castration-resistant prostate cancer.
Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of metastatic, castration-resistant prostate cancer].
von Amsberg G; Merseburger AS
Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
[TBL] [Abstract][Full Text] [Related]
14. The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments.
Nemes A; Tomuleasa C; Kacso G
J BUON; 2014; 19(2):357-64. PubMed ID: 24965392
[TBL] [Abstract][Full Text] [Related]
15. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
[TBL] [Abstract][Full Text] [Related]
17. Therapy Update for Metastatic Castration-Resistant Prostate Cancer.
Dinh JA; Baker D; Chahal M
Consult Pharm; 2016; 31(10):581-592. PubMed ID: 27725068
[TBL] [Abstract][Full Text] [Related]
18. Castration-resistance prostate cancer: what is in the pipeline?
DE Nunzio C; Presicce F; Giacinti S; Bassanelli M; Tubaro A
Minerva Urol Nefrol; 2018 Feb; 70(1):22-41. PubMed ID: 28707844
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
Sonpavde G; Wang CG; Galsky MD; Oh WK; Armstrong AJ
BJU Int; 2015 Jul; 116(1):17-29. PubMed ID: 25046451
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]